Physician profile
Dosik Kim
NPI 1336237817
$5,591.32
in general payments reported to CMS, 2019-2025
25 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $216 · 2021: $412 · 2022: $741 · 2023: $1,218 · 2024: $879 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,053 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.66 |
| Education | $288.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,139.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Harmony Biosciences LLC | $995.14 | 2021-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $675.65 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $558.13 | 2022-2025 | Sunosi |
| Philips North America LLC | $325.04 | 2019-2025 | (B090) Home Pi Undivided, Acute Care Pi Undivided |
| Jazz Pharmaceuticals INC. | $295.73 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.25 | 2019-2022 | |
| Mylan Specialty L.P. | $258.88 | 2019-2020 | |
| Genentech USA, INC. | $163.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $149.80 | 2020-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $137.39 | 2019-2020 | |
| Fisher & Paykel Healthcare INC | $127.04 | 2023-2025 | Fisher & Paykel Healthcare |
| Insmed, INC. | $102.84 | 2019-2025 | Brinsupri, Arikayce |
| Electromed, INC. | $85.24 | 2022 | |
| Resmed Corp | $68.14 | 2022-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.65 | 2019 | |
| Baxter Healthcare | $39.15 | 2023 | Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $34.40 | 2025 | Glassia |
| Merck Sharp & Dohme LLC | $32.12 | 2023 | Belsomra |
| Shire North American Group INC | $27.36 | 2019 | |
| Lilly USA, LLC | $16.93 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $14.01 | 2019 | |
| Optinose US, INC. | $12.15 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.89 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dosik Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.